6533b7d8fe1ef96bd1269ae8
RESEARCH PRODUCT
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
N. PuigLuis Antonio Corchete SánchezJ. J. Pérez-moránJ. DávilaT. PaínoJ. De La RubiaAlbert OriolJ. Martín-sánchezF. De ArribaJ. BladéM. J. BlanchardV. González-calleR. Garcia-sanzBruno PaivaJ. J. LahuertaJ. F. San-miguelM. V. MateosE. M. OcioUniversitat Autònoma De Barcelonasubject
0301 basic medicineOncologyMelphalanCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdverse effectMultiple myelomaPneumonitisbusiness.industryLate effectImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuation030104 developmental biologymyelomaOncology030220 oncology & carcinogenesispembrolizumabimmunotherapymedicine.symptombusinessconsolidationmedicine.drugdescription
PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007
year | journal | country | edition | language |
---|---|---|---|---|
2020-12-03 |